Sort   by:  
 Page size 
UnknownFirst-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
Not available
S-EPMC5648176 | biostudies-literature
UnknownLong-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.
Not available
S-EPMC5721228 | biostudies-literature
UnknownSeven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
Not available
S-EPMC3478574 | biostudies-literature
UnknownExpanding the diversity of mycobacteriophages: insights into genome architecture and evolution.
Not available
S-EPMC3029335 | biostudies-literature
UnknownTime to establish an international vaccine candidate pool for potential highly infectious respiratory disease: a community's view.
Not available
S-EPMC10550631 | biostudies-literature
UnknownDeep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis.
Not available
S-EPMC11910230 | biostudies-literature
UnknownChronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults.
Not available
S-EPMC4818564 | biostudies-literature
UnknownNeutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Not available
S-EPMC11797383 | biostudies-literature
UnknownAltered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
Not available
S-EPMC8942856 | biostudies-literature
UnknownTocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355 | biostudies-literature
Sort   by:  
 Page size